Global Wealth Management Investment Advisory Inc. Raises Position in Amgen Inc. $AMGN

Posted by Geri Gentry on May 13th, 2026

Global Wealth Management Investment Advisory Inc. raised its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 18.8% during the fourth quarter, HoldingsChannel reports. The firm owned 15,504 shares of the medical research company’s stock after buying an additional 2,448 shares during the quarter. Global Wealth Management Investment Advisory Inc.’s holdings in Amgen were worth $5,075,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Dogwood Wealth Management LLC grew its stake in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the last quarter. Anfield Capital Management LLC boosted its holdings in Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after acquiring an additional 70 shares during the period. Board of the Pension Protection Fund bought a new position in Amgen in the 4th quarter valued at $26,000. Manning & Napier Advisors LLC grew its position in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC bought a new position in Amgen in the 4th quarter valued at $33,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN stock opened at $336.29 on Wednesday. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The stock has a market capitalization of $181.49 billion, a price-to-earnings ratio of 23.40, a P/E/G ratio of 3.31 and a beta of 0.44. The stock has a fifty day simple moving average of $352.03 and a two-hundred day simple moving average of $342.49. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business had revenue of $8.62 billion during the quarter, compared to analysts’ expectations of $8.58 billion. During the same period in the prior year, the business earned $4.90 EPS. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. On average, analysts predict that Amgen Inc. will post 22.36 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.15%.

Wall Street Analyst Weigh In

Several brokerages have commented on AMGN. Morgan Stanley set a $332.00 price objective on Amgen in a research report on Friday, May 1st. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $350.00 price target on shares of Amgen in a research note on Wednesday, April 8th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research note on Thursday, February 5th. Sanford C. Bernstein downgraded shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research note on Tuesday, January 20th. Finally, Daiwa Securities Group raised their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research note on Tuesday, February 10th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $357.12.

View Our Latest Stock Analysis on AMGN

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.85% of the company’s stock.

Amgen Profile

(Free Report)

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.